# Novel ADC Could Expand Treatment Options in Ovarian Cancer

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/esmofuturefocus/123950) · 2026-11-18 · Medicine
Page: https://themorning.science/story/novel-adc-could-expand-treatment-options-in-ovarian-cancer-ad5b2926be3ee3c2
Kind: research · Impact: medium

## In brief

- Updated results from the FONTANA trial were presented at the annual European Society for Medical Oncology (ESMO) congress.
- The investigational antibody-drug conjugate (ADC) torvutatug samrotecan showed promising activity in ovarian cancer.

## Why it matters

If confirmed in further studies, this investigational ADC could expand treatment options for ovarian cancer. The available source excerpt does not give detailed efficacy figures.

## Coverage

- [Novel ADC Could Expand Treatment Options in Ovarian Cancer](https://www.medpagetoday.com/meetingcoverage/esmofuturefocus/123950) — MedPageToday.com - medical news for physicians, 2026-11-18

Tags: ovarian cancer, antibody-drug conjugate, clinical trial, oncology, esmo

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
